Edgardo Santos MD, FACP, FCCP, discusses how cancer centers across the United States are minimizing the negative effects of the ongoing carboplatin and cisplatin shortage, and details potential next steps that should be taken to prevent drug shortages like this from occurring in the future.
Solange Peters, MD, PhD, discusses steps being taken to address the ongoing platinum chemotherapy shortage in the United States for patients with cancer.
Heather Wakelee, MD, FASCO, discusses unmet needs in cancer care stemming from the ongoing platinum chemotherapy shortage in the United States, highlighting the need for newer, better drugs to help treat patients.
Edward S. Kim, MD, MBA, discusses drug shortages in cancer care, detailing how City of Hope has continued to establish efforts to mitigate the effects of these shortages.
Nancy U. Lin, MD, discusses selecting between systemic vs local therapy for patients with HER2-positive breast cancer displaying central nervous system metastases.
Roger Li, MD, expands on the mechanism of action for the combination of CG0070 and pembrolizumab, and discusses the rationale for investigating the regimen's synergy in patients with non–muscle invasive bladder cancer who are unresponsive to Bacillus Calmette-Guérin.
Deborah B. Doroshow, MD, PhD, discusses the similarities and differences between the efficacy and safety profiles of pralsetinib and selpercatinib in patients with non–small cell lung cancer harboring RET fusions.
Erminia Massarelli MD, PhD, MS, discusses efficacy and safety data with the NTRK inhibitors larotrectinib and entrectinib in patients with non–small cell lung cancer harboring NTRK fusions.
Yara Abdou, MD, discusses treatment sequencing with CDK4/6 inhibitors across all lines of therapy in patients with hormone receptor–positive, HER2-negative breast cancer.
Amanda Bloomer, PhD, discusses the rationale for launching the ColoCare study, an investigation into the health-related quality of life outcomes of younger vs older adult patients with newly diagnosed colorectal cancer.
Matthew J. Frank, MD, PhD, discusses remaining questions regarding treatment sequencing following preliminary results from a phase 1 trial of a CD22-directed CAR-T therapy in relapsed/refractory large B-cell lymphoma.
Heather Wakelee, MD, FASCO, discusses the clinical significance of updated data from several key trials evaluating perioperative immunotherapy in early-stage non–small cell lung cancer.
Natasha Kwendakwema, MD, discusses findings from a study on the effects of adverse financial events on treatment costs at the end of life and health care utilization in patients with cancer.
Marina Kremyanskaya, MD, PhD, discusses the rationale for investigating rusfertide in the phase 2 REVIVE trial for patients with phlebotomy-dependent polycythemia vera.
Paul Sieber, MD, discusses the importance of evaluating comorbidities in patients with prostate cancer, including assessing risk factors for cardiovascular events in those who are initiating androgen deprivation therapy.
Mohamad Mohty, MD, PhD, discusses the promise of the phase 2 MagnetisMM-3 trial in patients with relapsed/refractory multiple myeloma, which is investigating elranatamab monotherapy in this patient population.
Hiba Khan, MD, MPH, discusses how adverse financial events may contribute to the risk of early mortality in patients with cancer.
Edward S. Kim, MD, MBA, discusses the importance of the Bridging the Gaps in Lung Cancer meeting, and expands on the importance of educating clinicians on how to best implement new developments within lung cancer to address these gaps in care.
David Ziegler, MD, PhD, discusses findings from the phase 2 FIREFLY-1 trial of tovorafenib in pediatric patients with low-grade glioma.
Bhavana “Tina” Bhatnagar, DO, discusses the investigation of minimal residual disease negativity in patients with acute myeloid leukemia.
Adnan F. Danish, MD, discusses the methodologies behind the use of SCINTIX radiation technology in metastatic bone and lung tumors, detailing how this technology differs from computed tomography or magnetic resonance imaging scans prior to treatment.
Yara Abdou, MD, discusses the considerations between AKT inhibitors vs PI3K inhibition in patients with hormone receptor-positive, HER2-negative breast cancer.
Prioty Islam, MD, MSc, discusses the impact of the updated safety and efficacy data seen with FDA-approved BTK inhibitors in patients with chronic lymphocytic leukemia.
Millie Das, MD, discusses the current landscape of new and emerging ADCs under investigation in small-cell lung cancer and highlights the phase 2 SWOG S1929 study.
George Lau, MD, FRCP, FAASLD, discusses clinical implications for the use of dual checkpoint inhibition in HCC based on an analysis of immune-related adverse effects seen with the STRIDE regimen in the phase 3 HIMALAYA trial.
Isabelle Franklin, discusses the investigation of the correlation between self-reported social needs and colorectal cancer screening.
Luciano J. Costa, MD, PhD, discusses the background of the phase 2 MASTER trial in newly diagnosed multiple myeloma.
Prioty Islam, MD, MSc, discusses the importance of shared decision making between patients and clinicians when selecting among available BTK inhibitors in the treatment of chronic lymphocytic leukemia or mantle cell lymphoma.
Maxine Sun, PhD, MPH, discusses ongoing research efforts dedicated to examining the relationship between clonal hematopoiesis and cardiovascular disease in patients with renal cell carcinoma.
